Topical 5% ET-02 Increased Hair Growth in 28 Days Compares Favorably with Reported Results for Topical and Oral Minoxidil Phase 2 Clinical Trial Expected to Begin in 2027 WOBURN, Mass., Sept. 16, 2026 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, today announced that the company will make a scientific presentation about its product candidate ET-02 for androgenetic alopecia at the Third BCN Hair Mee

Total national coverage footprint for PENFS increases to over 120 million covered livesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The

SAN FRANCISCO--(BUSINESS WIRE)--Loyal, a clinical-stage animal health company developing longevity drugs for dogs, announced today that LOY-003, a pill designed to extend the lifespans of large dogs, completed the Reasonable Expectation of Effectiveness (RXE) section of its Expanded Conditional Approval (XCA) application. Since the FDA opened the XCA pathway to encourage novel drug development for unmet clinical needs in 2019, Loyal has created a new category of preventive medicines that target

SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced today that the U.S. Patent and Trademark Office (USPTO) has officially granted a patent (Patent No. US12,735,481) for its proprietary, core bispecific antibody technology platform, PACbody® (PAC = Pairing of Alternative Cysteines). This patent grant marks a significant milestone for Phanes in its fou

Approximately 50% of people don't adhere to their chronic treatment regimens, a gap that has historically been impossible for health plans to close at scale As part of RadiantGraph's core platform, these Agents will bring existing voice engagement into ongoing, condition-specific care management that operate within a non-diagnostic scope RadiantGraph was approved for CMS's ACCESS program, a Medicare initiative that compensates healthcare organizations for delivering technology-enabled chronic ca

IRVINE, Calif., Sept. 16, 2026 /PRNewswire/ -- Zymo Research, a leader in biotechnology and protein engineering, demonstrated top-tier performance in the AIntibody Design Challenge, an international benchmark of AI-driven antibody discovery inspired by the Critical Assessment of Structure Prediction (CASP). In the affinity maturation challenge, Zymo Research's computational protein engineering platform ranked among the top four teams, generating antibody variants with substantially improved bind

Growth investment will expand Climb's Databricks partnership, advance healthcare, life sciences and financial services solutions, and accelerate its agentic delivery operations framework. DALLAS, Sept. 16, 2026 /PRNewswire/ -- Climb, a Databricks-native data and AI consultancy, today announced a growth investment from RLH Equity Partners, a Los Angeles-based investment firm focused on founder-led, technology-driven businesses. Founded in 2026, Climb has already assembled a team of senior data an

Innovative home-based Acute Care at Home™ program helped improve outcomes for more than 1,000 general medicine patients in Brooklyn BROOKLYN, N.Y., Sept. 16, 2026 /PRNewswire/ -- Maimonides Health, Brooklyn's largest healthcare system, and myLaurel, a leading tech-enabled home-based acute and transitional care company, today announced the one-year results of their strategic partnership. Initially launched in May 2025, the collaboration represents a highly integrated clinical effort that has succ

BOULDER, Colo., Sept. 16, 2026 /PRNewswire/ -- Ambrosia Biosciences Inc. ("Ambrosia") today announced that company management will participate in the following investor conferences: Tuesday, September 22, 2026: Bernstein Best of Biotech Symposium 2.0 Thursday, September 24, 2026: BofA Securities Healthcare Trailblazers Private Company Conference Tuesday, September 29, 2026: Oppenheimer Private Life Sciences Company Showcase About Ambrosia Biosciences Inc. Ambrosia Biosciences Inc. is a privately

New Institutional Special Needs Plan will expand coordinated care support for nursing home and assisted living residents beginning in 2027 CEDAR FALLS, Iowa, Sept. 16, 2026 /PRNewswire/ -- Curana Health today announced that it will be expanding its Align Senior Care into Iowa, offering Iowans an Institutional Special Needs Plan (I-SNP) designed specifically for nursing home and assisted living residents across 41 Iowa counties. Enrollment will begin October 1, 2026, with benefits effective Janu